Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors.
Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors.
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors. It highlights…
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies.
Adapter-based CAR T cells face hurdles in treating solid tumors and blood cancers.
This narrative review examines the potential of adapter-based CAR T cells across multiple cancer types, including solid tumors and hematolog…
A review highlights that making these cells is hard work and they struggle against solid tumors, limiting their current use.
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations. Tumor r…
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data.
First CAR-T for Pancreatic Cancer Approved
This narrative review addresses the application of CAR-T cell therapy for pancreatic ductal adenocarcinoma. However, the source explicitly s…
For the first time, a new drug approved for pancreatic cancer uses immune cells to attack solid tumors instead of just blood cancers.
CAR T-cell optimization strategies are reviewed for hematologic cancers, solid tumors, and immune-mediated diseases.
Can fixing CAR T-cells in multiple ways finally make them safer and more effective for cancer patients?
This systematic review evaluates CAR T-cell therapy optimization strategies involving genetic, epigenetic, metabolic, and microenvironmental…
Fixing CAR T-cells across genetics, metabolism, and environment offers a safer, more effective path for treating blood cancers, solid tumors…
Ifinatamab deruxtecan shows antitumor activity in advanced treatment-refractory solid tumors in phase 1/2 trial
Early trial shows experimental drug shrinks tumors in some patients with advanced cancers
This first-in-human phase 1/2 trial of 97 patients with advanced treatment-refractory solid tumors found a confirmed objective response rate…
An early trial of a new experimental drug shrank tumors in 34% of patients with advanced cancers that had stopped responding to standard tre…
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Review describes biological barriers to CAR-T therapy in solid tumors and engineering strategies
Review explores challenges and potential solutions for CAR-T therapy in solid tumors
A systematic review synthesizing literature on CAR-T cell therapy for solid tumors found clinical efficacy remains modest and inconsistent d…
Solid tumors block CAR-T cells from reaching cancer, but new engineering strategies aim to overcome these barriers for better treatment.
Comprehensive genomic profiling finds 0.2% NTRK fusion prevalence across solid tumors in community health system
Study finds rare NTRK gene fusions in 0.2% of solid tumors in community health system
An observational cohort study of 15128 adult patients with solid tumors in a community health system found a 0.2% prevalence of pathogenic N…
Only 0.2% of solid tumors in a large community health system carry rare NTRK gene fusions, yet testing found eight new fusion types never de…